What Next for J&J's Orthopedic Business?
Executive SummaryIt's been a widely-held belief that the US orthopedics business is poised for consolidation, that the current market structure, which has nearly ten companies with measurable market share, is untenable. Many also believe that the most likely consolidator is Johnson & Johnson Professional Inc. Then why hasn't J&J made a major move?
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.